Table 1.

Baseline patient, tumor, and treatment characteristics of the overall cohort stratified by NLR ≤ 4.0 and NLR > 4.0 groups.

Variable	All Patients (N = 389)	NLR ≤ 4.0 (N = 275)	NLR > 4.0 (N = 114)	P value
Pretreatment NLR				<0.0001*
Median (range)	3.0 (0.4–42)	2.4 (0.4–4)	5.3 (4.1–42)
Age				0.24
Median (range)	71 (49–93)	71 (49–93)	72 (53–90)
Gender				0.99
Male	378 (97.2%)	267 (97.1%)	111 (97.4%)
Female	11 (2.8%)	8 (2.9%)	3 (2.6%)
Charlson Score				0.46
0	83 (21.3%)	61 (22.1%)	22 (19.3%)
1	141 (36.2%)	103 (37.5%)	38 (33.3%)
2+	165 (42.5%)	111 (40.4%)	54 (47.4%)
Race				0.01*
White	335 (86.1%)	229 (83.3%)	106 (93.0%)
Black	54 (13.9%)	46 (16.7%)	8 (7.0%)
Smoker at Diagnosis				0.74
Yes	167 (42.9%)	120 (43.6%)	47 (41.2%)
No	222 (57.1%)	155 (56.4%)	67 (58.8%)
Histology				0.42
Adenocarcinoma	162 (41.6%)	120 (43.6%)	42 (36.9%)
Squamous	156 (40.1%)	105 (38.2%)	51 (44.7%)
Other/unknown	71 (18.3%)	50 (18.2%)	21 (18.4%)
T stage
< 2 cm (T1a)	166 (42.7%)	118 (42.9%)	48 (42.1%)	0.57
2-3 cm (T1b)	143 (36.8%)	104 (37.8%)	39 (34.2%)
3-5 cm (T2a)	80 (20.5%)	53 (19.3%)	27 (23.7%)
Total BED (Gy10)				0.96
Median (range)	112.5 (100–187.5)	112.5 (100–187.5)	112.5 (100–180)
White Blood Cell Count (K/μL)				<0.0001*
Median (range)	8.0 (2.9–22.5)	7.5 (2.9–22.5)	9.1 (5–22.1)
Absolute Neutrophil Count (K/μL)				<0.0001*
Median (range)	5.1 (0.8–19.6)	4.5 (0.8–12.1)	6.7 (2.6–19.6)
Absolute Lymphocyte Count (K/μL)				<0.0001*
Median (range)	1.6 (0.1–13.5)	1.8 (0.4–13.5)	1.2 (0.1–12.5)
Pretreatment FEV1	(N = 229)	(N = 162)	(N = 67)	0.96
≤ 30%	22 (9.6%)	15 (9.3%)	7 (10.5%)
31-50%	71 (31.0%)	49 (30.2%)	22 (32.8%)
51-80%	103 (45.0%)	74 (45.7%)	29 (43.3%)
> 80%	33 (14.4%)	24 (14.8%)	9 (13.4%)